眼肌型重症肌无力全身型转化的影响因素分析
Analysis of Risk Factor for Progression from Ocular Myasthenia Gravis to Generalized Myasthenia Gravis
DOI: 10.12677/jcpm.2025.45469, PDF,    科研立项经费支持
作者: 林清睿*：济宁医学院临床医学院(附属医院)，山东 济宁；宋 艳#：济宁医学院附属医院神经内科，山东 济宁
关键词: 眼肌型重症肌无力；全身型重症肌无力；转化；影响因素；Ocular Myasthenia Gravis； Generalized Myasthenia Gravis； Conversion； Risk Factor
摘要: 重症肌无力是一种由自身抗体介导的累及神经肌肉接头导致传递功能障碍的自身免疫性疾病。眼肌型重症肌无力作为重症肌无力的一种重要的临床亚型，其特征是症状仅局限于眼部肌群，虽然较全身型重症肌无力症状轻且预后较好，但约半数的患者在疾病发展过程中会进展为全身型重症肌无力。眼肌型重症肌无力全身型转化受到性别、年龄、抗体类型、首发症状、合并疾病、生活习惯、机体免疫状态及免疫治疗等的影响，在不同的人群中表现出不同的转化率。这些因素通过各自的途径影响眼肌型重症肌无力向全身型重症肌无力转化。因此，识别能够影响眼肌型重症肌无力全身型转化的因素，对于高危患者早期诊断并进行干预，以争取良好预后具有重要的临床意义。
Abstract: Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder affecting the neuromuscular junction, leading to impaired synaptic transmission. Ocular myasthenia gravis (OMG), a significant clinical subtype of MG, is characterized by symptoms confined exclusively to the ocular muscles. Although OMG typically presents with milder symptoms and a more favorable prognosis compared to generalized myasthenia gravis (GMG), approximately half of OMG patients will progress to GMG during the disease course. The progression from OMG to GMG is influenced by factors including sex, age, antibody profile, initial symptoms, comorbidities, lifestyle habits, immune status, and immunotherapy, resulting in variable conversion rates across different populations. These factors contribute to the progression from OMG to GMG through distinct mechanisms. Consequently, identifying factors that influence the progression from OMG to GMG is of significant clinical importance for early diagnosis and intervention in high-risk patients, aiming to achieve favorable outcomes.
文章引用：林清睿, 宋艳. 眼肌型重症肌无力全身型转化的影响因素分析[J]. 临床个性化医学, 2025, 4(5): 121-129. https://doi.org/10.12677/jcpm.2025.45469

参考文献

[1] Berrih-Aknin, S. (2014) Myasthenia Gravis: Paradox versus Paradigm in Autoimmunity. Journal of Autoimmunity, 52, 1-28. [Google Scholar] [CrossRef] [PubMed]
[2] Uzawa, A., Ozawa, Y., Yasuda, M., Oda, F., Kojima, Y., Kawaguchi, N., et al. (2020) Increased Serum Acetylcholine Receptor Α1 Subunit Protein in Anti-Acetylcholine Receptor Antibody-Positive Myasthenia Gravis. Journal of Neuroimmunology, 339, Article ID: 577125. [Google Scholar] [CrossRef] [PubMed]
[3] Rath, J., et al. (2020) Frequency and Clinical Features of Treatment-Refractory Myasthenia Gravis. Journal of Neurology, 267, 1004-1011.
[4] Grob, D., Brunner, N., Namba, T. and Pagala, M. (2007) Lifetime Course of Myasthenia Gravis. Muscle & Nerve, 37, 141-149. [Google Scholar] [CrossRef] [PubMed]
[5] Sieb, J.P. (2014) Myasthenia Gravis: An Update for the Clinician. Clinical and Experimental Immunology, 175, 408-418. [Google Scholar] [CrossRef] [PubMed]
[6] Luchanok, U. and Kaminski, H.J. (2008) Ocular Myasthenia: Diagnostic and Treatment Recommendations and the Evidence Base. Current Opinion in Neurology, 21, 8-15. [Google Scholar] [CrossRef] [PubMed]
[7] Patil-Chhablani, P., Nair, A., Venkatramani, D. and Gandhi, R. (2014) Ocular Myasthenia Gravis: A Review. Indian Journal of Ophthalmology, 62, 985-991. [Google Scholar] [CrossRef] [PubMed]
[8] Kupersmith, M.J., Latkany, R. and Homel, P. (2003) Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis. Archives of Neurology, 60, 243-248. [Google Scholar] [CrossRef] [PubMed]
[9] Allen, J.A., Scala, S. and Jones, H.R. (2009) Ocular Myasthenia Gravis in a Senior Population: Diagnosis, Therapy, and Prognosis. Muscle & Nerve, 41, 379-384. [Google Scholar] [CrossRef] [PubMed]
[10] Hendricks, T.M., Bhatti, M.T., Hodge, D.O. and Chen, J.J. (2019) Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. American Journal of Ophthalmology, 205, 99-105. [Google Scholar] [CrossRef] [PubMed]
[11] Apinyawasisuk, S., Chongpison, Y., Thitisaksakul, C. and Jariyakosol, S. (2020) Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients with Positive Acetylcholine Receptor Antibody. American Journal of Ophthalmology, 209, 10-17. [Google Scholar] [CrossRef] [PubMed]
[12] Mazzoli, M., Ariatti, A., Valzania, F., Kaleci, S., Tondelli, M., Nichelli, P.F., et al. (2017) Factors Affecting Outcome in Ocular Myasthenia Gravis. International Journal of Neuroscience, 128, 15-24. [Google Scholar] [CrossRef] [PubMed]
[13] Delpy, L., Douin-Echinard, V., Garidou, L., Bruand, C., Saoudi, A. and Guéry, J. (2005) Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses. The Journal of Immunology, 175, 5050-5057. [Google Scholar] [CrossRef] [PubMed]
[14] Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., et al. (2016) Clinical Features, Pathogenesis, and Treatment of Myasthenia Gravis: A Supplement to the Guidelines of the German Neurological Society. Journal of Neurology, 263, 1473-1494. [Google Scholar] [CrossRef] [PubMed]
[15] Mantegazza, R., Cordiglieri, C., Consonni, A. and Baggi, F. (2016) Animal Models of Myasthenia Gravis: Utility and Limitations. International Journal of General Medicine, 9, 53-64. [Google Scholar] [CrossRef] [PubMed]
[16] Berrih-Aknin, S., Frenkian-Cuvelier, M. and Eymard, B. (2014) Diagnostic and Clinical Classification of Autoimmune Myasthenia Gravis. Journal of Autoimmunity, 48, 143-148. [Google Scholar] [CrossRef] [PubMed]
[17] Ducci, R.D., Kay, C.S.K., Fustes, O.J.H., Werneck, L.C., Lorenzoni, P.J. and Scola, R.H. (2021) Myasthenia Gravis during Pregnancy: What Care Should Be Taken? Arquivos de Neuro-Psiquiatria, 79, 624-629. [Google Scholar] [CrossRef] [PubMed]
[18] Andersen, J.B., Gilhus, N.E. and Sanders, D.B. (2016) Factors Affecting Outcome in Myasthenia Gravis. Muscle & Nerve, 54, 1041-1049. [Google Scholar] [CrossRef] [PubMed]
[19] Peeler, C.E., De Lott, L.B., Nagia, L., Lemos, J., Eggenberger, E.R. and Cornblath, W.T. (2015) Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis. JAMA Neurology, 72, 1170-1174. [Google Scholar] [CrossRef] [PubMed]
[20] Alkhawajah, N.M. and Oger, J. (2013) Late-Onset Myasthenia Gravis: A Review When Incidence in Older Adults Keeps Increasing: Late-Onset MG. Muscle & Nerve, 48, 705-710. [Google Scholar] [CrossRef] [PubMed]
[21] Gratton, S.M., Herro, A.M., Feuer, W.J. and Lam, B.L. (2016) Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis. Journal of Neuro-Ophthalmology, 36, 37-40. [Google Scholar] [CrossRef] [PubMed]
[22] Bojikian, K.D. and Francis, C.E. (2019) Thyroid Eye Disease and Myasthenia Gravis. International Ophthalmology Clinics, 59, 113-124. [Google Scholar] [CrossRef] [PubMed]
[23] Guo, R., Gao, T., Ruan, Z., Zhou, H., Gao, F., Xu, Q., et al. (2021) Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study. Neurology and Therapy, 11, 73-86. [Google Scholar] [CrossRef] [PubMed]
[24] Galassi, G., Mazzoli, M., Ariatti, A., Kaleci, S., Valzania, F. and Nichelli, P.F. (2018) Antibody Profile May Predict Outcome in Ocular Myasthenia Gravis. Acta Neurologica Belgica, 118, 435-443. [Google Scholar] [CrossRef] [PubMed]
[25] Wilson, L. and Davis, H. (2023) The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review. British and Irish Orthoptic Journal, 19, 108-119. [Google Scholar] [CrossRef] [PubMed]
[26] Cavalcante, P., Le Panse, R., Berrih‐aknin, S., Maggi, L., Antozzi, C., Baggi, F., et al. (2011) The Thymus in Myasthenia Gravis: Site of “Innate Autoimmunity”? Muscle & Nerve, 44, 467-484. [Google Scholar] [CrossRef] [PubMed]
[27] Li, H., Ruan, Z., Gao, F., Zhou, H., Guo, R., Sun, C., et al. (2021) Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study. Neurotherapeutics, 18, 2449-2457. [Google Scholar] [CrossRef] [PubMed]
[28] Kamarajah, S.K., Sadalage, G., Palmer, J., Carley, H., Maddison, P. and Sivaguru, A. (2017) Ocular Presentation of Myasthenia Gravis: A Natural History Cohort. Muscle & Nerve, 57, 622-627. [Google Scholar] [CrossRef] [PubMed]
[29] Kısabay, A., Özdemir, H.N., Gökçay, F. and Çelebisoy, N. (2021) Risk for Generalization in Ocular Onset Myasthenia Gravis: Experience from a Neuro-Ophthalmology Clinic. Acta Neurologica Belgica, 122, 337-344. [Google Scholar] [CrossRef] [PubMed]
[30] Gilhus, N.E., Nacu, A., Andersen, J.B. and Owe, J.F. (2014) Myasthenia Gravis and Risks for Comorbidity. European Journal of Neurology, 22, 17-23. [Google Scholar] [CrossRef] [PubMed]
[31] Zhong, H., Zhao, C. and Luo, S. (2019) HLA in Myasthenia Gravis: From Superficial Correlation to Underlying Mechanism. Autoimmunity Reviews, 18, Article ID: 102349. [Google Scholar] [CrossRef] [PubMed]
[32] Voight, B.F. and Cotsapas, C. (2012) Human Genetics Offers an Emerging Picture of Common Pathways and Mechanisms in Autoimmunity. Current Opinion in Immunology, 24, 552-557. [Google Scholar] [CrossRef] [PubMed]
[33] Li, F., Zhang, H., Tao, Y., Stascheit, F., Han, J., Gao, F., et al. (2022) Prediction of the Generalization of Myasthenia Gravis with Purely Ocular Symptoms at Onset: A Multivariable Model Development and Validation. Therapeutic Advances in Neurological Disorders, 15, 1-14. [Google Scholar] [CrossRef] [PubMed]
[34] Menon, D., Alharbi, M., Katzberg, H.D., Bril, V., Mendoza, M.G. and Barnett-Tapia, C. (2024) Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis. Neurology, 103, e209722. [Google Scholar] [CrossRef] [PubMed]
[35] Zhao, S., Yan, X., Ding, J., Ren, K., Sun, S., Lu, J., et al. (2022) Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis with Pure Ocular Onset. Frontiers in Neurology, 13, Article 857402. [Google Scholar] [CrossRef] [PubMed]
[36] Barnett, C. and Bril, V. (2020) New Insights into Very-Late-Onset Myasthenia Gravis. Nature Reviews Neurology, 16, 299-300. [Google Scholar] [CrossRef] [PubMed]
[37] Al-Haidar, M., Benatar, M. and Kaminski, H.J. (2018) Ocular Myasthenia. Neurologic Clinics, 36, 241-251. [Google Scholar] [CrossRef] [PubMed]
[38] Kim, K.H., Kim, S.W. and Shin, H.Y. (2021) Initial Repetitive Nerve Stimulation Test Predicts Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis. Journal of Clinical Neurology, 17, 265-272. [Google Scholar] [CrossRef] [PubMed]
[39] Teo, K.Y., Tow, S.L., Haaland, B., Gosavi, T.D., et al. (2017) Low Conversion Rate of Ocular to Generalized Myasthenia Gravis in Singapore. Muscle & Nerve, 57, 756-760. [Google Scholar] [CrossRef] [PubMed]
[40] Sarrigiannis, P.G., Kennett, R.P., Read, S. and Farrugia, M.E. (2005) Single‐Fiber EMG with a Concentric Needle Electrode: Validation in Myasthenia Gravis. Muscle & Nerve, 33, 61-65. [Google Scholar] [CrossRef] [PubMed]
[41] Guan, Y., Cui, L., Liu, M. and Niu, J. (2015) Single-Fiber Electromyography in the Extensor Digitorum Communis for the Predictive Prognosis of Ocular Myasthenia Gravis. Chinese Medical Journal, 128, 2783-2786. [Google Scholar] [CrossRef] [PubMed]
[42] Hu, Y., Wang, J., Rao, J., Xu, X., Cheng, Y., Yan, L., et al. (2020) Comparison of Peripheral Blood B Cell Subset Ratios and B Cell-Related Cytokine Levels between Ocular and Generalized Myasthenia Gravis. International Immunopharmacology, 80, Article ID: 106130. [Google Scholar] [CrossRef] [PubMed]
[43] Brusko, T.M., Putnam, A.L. and Bluestone, J.A. (2008) Human Regulatory T Cells: Role in Autoimmune Disease and Therapeutic Opportunities. Immunological Reviews, 223, 371-390. [Google Scholar] [CrossRef] [PubMed]
[44] Masuda, M., Matsumoto, M., Tanaka, S., Nakajima, K., Yamada, N., Ido, N., et al. (2010) Clinical Implication of Peripheral CD4+CD25+ Regulatory T Cells and Th17 Cells in Myasthenia Gravis Patients. Journal of Neuroimmunology, 225, 123-131. [Google Scholar] [CrossRef] [PubMed]
[45] Zhang, Y., Wang, H., Chi, L. and Wang, W. (2009) The Role of FoxP3+CD4+CD25hi Tregs in the Pathogenesis of Myasthenia Gravis. Immunology Letters, 122, 52-57. [Google Scholar] [CrossRef] [PubMed]
[46] van de Veen, W., Stanic, B., Wirz, O.F., Jansen, K., Globinska, A. and Akdis, M. (2016) Role of Regulatory B Cells in Immune Tolerance to Allergens and Beyond. Journal of Allergy and Clinical Immunology, 138, 654-665. [Google Scholar] [CrossRef] [PubMed]
[47] Sun, F., Ladha, S.S., Yang, L., Liu, Q., Shi, S.X., Su, N., et al. (2014) Interleukin‐10 Producing‐B Cells and Their Association with Responsiveness to Rituximab in Myasthenia Gravis. Muscle & Nerve, 49, 487-494. [Google Scholar] [CrossRef] [PubMed]
[48] Kurosaki, T., Kometani, K. and Ise, W. (2015) Memory B Cells. Nature Reviews Immunology, 15, 149-159. [Google Scholar] [CrossRef] [PubMed]
[49] Ozawa, Y., Uzawa, A., Yasuda, M., Kojima, Y., Oda, F., Himuro, K., et al. (2020) Changes in Serum Complements and Their Regulators in Generalized Myasthenia Gravis. European Journal of Neurology, 28, 314-322. [Google Scholar] [CrossRef] [PubMed]
[50] 赵庆珠, 吴多池, 黎灵萍. 重症肌无力患者C3、C4、Th1/Th2水平与MG-ADL评分的关系及预测眼肌型向全身型转变的效能[J]. 中国医师杂志, 2022, 24(6): 911-915.
[51] Wei, S., Yang, C., Si, W., Dong, J., Zhao, X., Zhang, P., et al. (2024) Altered Serum Levels of Cytokines in Patients with Myasthenia Gravis. Heliyon, 10, e23745. [Google Scholar] [CrossRef] [PubMed]
[52] Uzawa, A., Akamine, H., Kojima, Y., Ozawa, Y., Yasuda, M., Onishi, Y., et al. (2021) High Levels of Serum Interleukin-6 Are Associated with Disease Activity in Myasthenia Gravis. Journal of Neuroimmunology, 358, Article ID: 577634. [Google Scholar] [CrossRef] [PubMed]
[53] Maurer, M., Bougoin, S., Feferman, T., Frenkian, M., Bismuth, J., Mouly, V., et al. (2015) IL-6 and Akt Are Involved in Muscular Pathogenesis in Myasthenia Gravis. Acta Neuropathologica Communications, 3, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[54] Wang, Z., Wang, W., Chen, Y. and Wei, D. (2012) T Helper Type 17 Cells Expand in Patients with Myasthenia‐associated Thymoma. Scandinavian Journal of Immunology, 76, 54-61. [Google Scholar] [CrossRef] [PubMed]
[55] Jing, L., Hou, Y., Wu, H., Miao, Y., Li, X., Cao, J., et al. (2015) Transcriptome Analysis of mRNA and miRNA in Skeletal Muscle Indicates an Important Network for Differential Residual Feed Intake in Pigs. Scientific Reports, 5, Article ID: 11953. [Google Scholar] [CrossRef] [PubMed]
[56] Sabre, L., Maddison, P., Wong, S.H., Sadalage, G., Ambrose, P.A., Plant, G.T., et al. (2019) miR‐30e‐5p as Predictor of Generalization in Ocular Myasthenia Gravis. Annals of Clinical and Translational Neurology, 6, 243-251. [Google Scholar] [CrossRef] [PubMed]
[57] Stosic-Grujicic, S., Stojanovic, I. and Nicoletti, F. (2009) MIF in Autoimmunity and Novel Therapeutic Approaches. Autoimmunity Reviews, 8, 244-249. [Google Scholar] [CrossRef] [PubMed]
[58] Sumaiya, K., Langford, D., Natarajaseenivasan, K. and Shanmughapriya, S. (2022) Macrophage Migration Inhibitory Factor (MIF): A Multifaceted Cytokine Regulated by Genetic and Physiological Strategies. Pharmacology & Therapeutics, 233, Article ID: 108024. [Google Scholar] [CrossRef] [PubMed]
[59] Greven, D., Leng, L. and Bucala, R. (2010) Autoimmune Diseases: MIF as a Therapeutic Target. Expert Opinion on Therapeutic Targets, 14, 253-264. [Google Scholar] [CrossRef] [PubMed]
[60] Bucala, R. (2012) MIF, MIF Alleles, and Prospects for Therapeutic Intervention in Autoimmunity. Journal of Clinical Immunology, 33, 72-78. [Google Scholar] [CrossRef] [PubMed]
[61] Huang, X., Li, H., Zhang, Z., Wang, Z., Du, X. and Zhang, Y. (2024) Macrophage Migration Inhibitory Factor: A Noval Biomarker Upregulates in Myasthenia Gravis and Correlates with Disease Severity and Relapse. Cytokine, 175, Article ID: 156485. [Google Scholar] [CrossRef] [PubMed]
[62] Zhang, Y., Zhang, J., Sheng, H., Li, H. and Wang, R. (2019) Acute Phase Reactant Serum Amyloid a in Inflammation and Other Diseases. Advances in Clinical Chemistry, 90, 25-80. [Google Scholar] [CrossRef] [PubMed]
[63] Sack, G.H. (2018) Serum Amyloid A—A Review. Molecular Medicine, 24, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[64] Buck, M., Gouwy, M., Wang, J., Snick, J., Opdenakker, G., Struyf, S., et al. (2016) Structure and Expression of Different Serum Amyloid a (SAA) Variants and Their Concentration-Dependent Functions during Host Insults. Current Medicinal Chemistry, 23, 1725-1755. [Google Scholar] [CrossRef] [PubMed]
[65] Sodin-Šemrl, S., Žigon, P., Čučnik, S., Kveder, T., Blinc, A., Tomšič, M., et al. (2006) Serum Amyloid a in Autoimmune Thrombosis. Autoimmunity Reviews, 6, 21-27. [Google Scholar] [CrossRef] [PubMed]
[66] Huang, X., An, X., Gao, X., Wang, N., Liu, J., Zhang, Y., et al. (2024) Serum Amyloid a Facilitates Expansion of CD4+ T Cell and CD19+ B Cell Subsets Implicated in the Severity of Myasthenia Gravis Patients. Journal of Neurochemistry, 168, 224-237. [Google Scholar] [CrossRef] [PubMed]